Lishan Biotech

What Lishan Biotech does

Shanghai Lishan Biomedical Co., Ltd. (上海力山生物医药有限公司) is a privately held, clinical-stage biopharmaceutical company founded in 2022 and headquartered in Shanghai's Zhangjiang Pharmaceutical Valley. Lishan pursues a dual-engine strategy combining Live Biotherapeutic Products (LBP) with targeted small molecule drugs across six pipeline assets targeting inflammatory bowel disease (Crohn's disease and ulcerative colitis), oncology (renal cell carcinoma, non-small cell lung cancer, liver cancer, methotrexate adverse reactions), and neurological disorders (autism spectrum disorder). The company's most advanced asset, LS-LBP-002 (originally BMC128, in-licensed from Evogene subsidiary Biomica in February 2026), completed Phase I in June 2026.

Lishan's technology stack rests on three core platforms. The Swarming Technology Platform is a globally pioneering approach leveraging bacterial swarming motility phenotypes for gut colonization, applied in LS-LBP-001 for Crohn's disease; the platform holds Chinese invention patents and international PCT protection. IMicAP (Intelligent Microbial Application Platform) is an AI-powered platform co-developed with Fudan University's Intelligent Medicine Research Institute since August 2023, integrating multi-omics data with proprietary models (MDTips, TransCDR, RDKG-115) for knowledge retrieval, zero-code bioinformatics, drug screening, and intelligent clinical enrollment. The Indolepropionic Acid Small Molecule Platform expands chemical space via microbial metabolite mimetics and underpins LS-SM-001 for ulcerative colitis. Supporting infrastructure includes a 1,000+ strain proprietary library (13 designated probiotic strains), a time-lapse photography incubator for swarming research, and a GMP-compliant LBP production process.

Lishan's business model is pre-revenue and structured around future drug commercialization paired with in-licensing of clinical-stage assets. Revenue mechanics will derive from (a) direct drug product sales post-NMPA/FDA/EMA approval, (b) milestone payments and tiered royalties owed to licensors such as Biomica, and (c) additional in-licensing transactions. Distribution will run through hospital procurement, pharmaceutical partnerships, and direct commercialization, with clinical operations executed via partnerships with Renji Hospital Punan Branch (clinical sites), Duozheng Bio (CRO), and Eglin Pharma (FDA/EMA regulatory). The company is founder-led by Chairman and CTO Dr. Chen Weijie and has 50+ R&D staff as of late 2025. No institutional investors or funding rounds are publicly disclosed.

Name

Lishan Biotech

Legal name

上海力山生物医药有限公司

Website

https://lishan.ltd

Company type

Private

Founded year

2022

Operating status

Operating

Short description

Lishan Biotech (上海力山生物医药有限公司) is a Shanghai-based clinical-stage biopharmaceutical company founded in 2022 that uses AI-enabled microbiome platforms to develop live biotherapeutic products and targeted small molecules for inflammatory bowel disease, oncology, and neurological disorders.

Ownership category

akta.pro rank

Product category

Microbiome Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Knowledge Management & Scientific Collaboration / Literature Intelligence (HLAGAJAN)

Keywords

• Live biotherapeutic products
• Microbiome therapeutics
• Inflammatory bowel disease drugs
• AI drug discovery
• Microbial small molecules

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Drug Development and Commercialization: As a pre-revenue clinical-stage biotech company, Lishan Biotech is developing live biotherapeutic products (LBP) and targeted small molecule drugs. Revenue will be generated through drug product sales upon regulatory approval and commercialization. The company holds global exclusive licensing rights for LS-LBP-002 and plans to pursue simultaneous regulatory submissions in China and the US.
2. Licensing and Milestone Payments: Through the exclusive global license agreement with Evogene/Biomica for BMC128 (LS-LBP-002), Lishan receives development milestone payments and tiered royalties upon commercialization.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Lishan Biotech is a clinical-stage biopharmaceutical company developing AI-enabled Live Biotherapeutic Products (LBP) and targeted small molecule drugs based on proprietary microbiome science. Its pipeline of six drug candidates targets inflammatory bowel disease (Crohn's disease and ulcerative colitis), oncology (renal cell carcinoma, non-small cell lung cancer, liver cancer), and neurological conditions (autism spectrum disorder). The company's drug discovery is powered by three proprietary platforms — the Swarming Technology Platform for gut bacteria colonization, the IMicAP AI platform for knowledge-driven drug screening, and the Indolepropionic Acid Small Molecule Platform — supported by a proprietary strain library of over 1,000 functional bacterial strains.

Product overview

Lishan Biotech operates a dual-engine platform strategy centered on 'AI + Microbiome', combining Live Biotherapeutic Products (LBP) with targeted small molecule drugs across six pipeline products. The product portfolio spans two technology platforms — the Swarming Technology Platform (applied in LS-LBP-001 for Crohn's disease) and the Indolepropionic Acid Small Molecule Platform (applied in LS-SM-001 for ulcerative colitis) — both powered by the IMicAP AI platform for knowledge retrieval, drug screening, and clinical enrollment optimization. The pipeline includes four LBP products (LS-LBP-001 through LS-LBP-004) targeting Crohn's disease, renal cell carcinoma, methotrexate adverse reactions, and autism spectrum disorder; and two small molecule drugs (LS-SM-001 for ulcerative colitis and LS-SM-002 for liver cancer). Supporting services include a time-lapse photography incubator for microbial research and a non-invasive IBD screening device ('卓微一号').

Differentiator

Problem solved

Functional benefit

Brands

• IMicAP (智能微生物应用平台): Intelligent Microbial Application Platform — an AI-powered platform co-developed with Fudan University for microbiome research, drug discovery, and clinical trial patient enrollment.

Products and services

• LS-LBP-001 (Live Biotherapeutic Product for Crohn's Disease) A live biotherapeutic product targeting Crohn's disease, based on Lishan Biotech's globally original Swarming technology. The product leverages swarming bacteria enriched in the intestinal inflammatory environment to migrate, colonize, and form a biofilm protective layer on damaged intestinal mucosa, achieving superior gut inflammation relief compared to conventional probiotics.
• LS-LBP-002 (Live Biotherapeutic Product for Oncology) A rationally designed live biotherapeutic product consisting of four defined human gut bacterial strains with confirmed functional properties, originally developed by Evogene subsidiary Biomica (BMC128). It enhances anti-tumor immune response and stimulates anti-tumor immune activity when combined with immunotherapy, targeting renal cell carcinoma, non-small cell lung cancer, and melanoma.
• LS-LBP-003 (Live Biotherapeutic Product for Chemotherapy Adverse Reactions)

Quantifiable outcome

• LS-LBP-001 pipeline completed Phase I pre-trial for Crohn's disease treatment
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability7 records

Feature4 records

Partnerships

Five partnerships are on record, tiered flagship/core, major and medium.

• Evogene Ltd. / Biomica Ltd.flagship/coreOEM/ Whitelabel/ Licensing Partner · 4 February 2026Exclusive global licensing agreement for BMC128 (now LS-LBP-002), a microbiome-based live biotherapeutic product for renal cell carcinoma, non-small cell lung cancer, and melanoma. Lishan holds full responsibility for global clinical development, manufacturing, and commercialization. Biomica receives milestone payments and tiered royalties upon commercialization.
• Duozheng Bio (都正生物)majorImplementation/ SI/ Consulting Partner · 19 June 2025Strategic cooperation for LBP clinical trials in IBD field. Duozheng Bio provides clinical trial design, execution, and regulatory registration services as a leading CRO. Cooperation planned to expand to metabolic diseases and tumor immunotherapy.
• Renji Hospital Punan Branch (仁济医院浦南分院)mediumStrategic or Co-development Partner · 21 March 2025Medical-industry integration cooperation covering: (1) Medical device cooperation - IBD non-invasive detection chip in laboratory and gastroenterology; (2) Research cooperation - gut microbiota-assisted molecular drug delivery and kidney disease-related microbiome screening; (3) Clinical cooperation - LBP pipeline IIT clinical trials at the hospital.
• Eglin Pharma (埃格林医药)majorStrategic or Co-development Partner · 5 June 2024Comprehensive strategic cooperation with a company founded by four former FDA review officials. Collaboration covers early candidate selection, clinical development and regulatory filing, and long-term business cooperation. Eglin provides FDA/EMA regulatory expertise and AI team capabilities.
• Fudan University Intelligent Medicine Research Institute (复旦大学智能医学研究院)flagship/coreStrategic or Co-development Partner · 1 August 2023Joint establishment of 'Intelligent Microbiome School-Enterprise Joint Laboratory'. The IMicAP platform leverages Fudan's precision medicine knowledge base and data support from 18 affiliated hospitals, combined with Lishan's early participation in the Human Microbiome Project.

Scale indicators6 records

Recent moves9 records

Expansion highlights7 records

Direct peers

• Enterome: France-based microbiome-derived drug company developing both LBPs and small-molecule oncology/IBD drugs from microbiome antigens. Closely mirrors Lishan's dual LBP + microbial-metabolite small-molecule strategy.
• Seres Therapeutics: U.S. clinical-stage microbiome therapeutics company developing defined-consortium LBPs (e.g., VOWST for recurrent C. difficile). Closest U.S. analogue to Lishan's LBP + small-molecule dual approach, with comparable IBD/oncology exploratory efforts and the same regulatory uncertainty.
• Assembly Biosciences: Clinical-stage biotech with a microbiome program (e.g., GI-focused and HBV-related microbiome assets). Comparable modality and clinical-stage risk profile, although focused on different therapeutic categories.
• Second Genome: U.S. microbiome drug discovery platform leveraging strain libraries and AI-driven screening. Direct peer on the combination of large bacterial strain library + computational/AIML-driven hit identification used in Lishan's discovery engine.
• MaaT Pharma: European clinical-stage microbiome company with LBPs for oncology (graft-vs-host disease) and IBD. Directly comparable on LBP modality, IBD/oncology indication focus, and European clinical-stage positioning.
• Vedanta Biosciences: Defined-consortium LBP platform company focused on IBD (ulcerative colitis, Crohn's), immune-mediated diseases and infectious disease. Directly comparable to Lishan's strain-library-backed approach and its 4-strain LS-LBP-002 consortium design.
• 4D pharma (now Biomica-adjacent assets): Predecessor UK LBP biotech with programs in oncology (e.g., MRx0518 for RCC) and IBD — directly overlapping with Lishan's LS-LBP-001/002 indications before its restructuring, providing a benchmark for LBP oncology positioning.
• Evogene / Biomica: Evogene (Nasdaq: EVGN) and its Biomica subsidiary are Lishan's exclusive global license partner for BMC128/LS-LBP-002. Direct peer in rationally-designed LBP oncology (RCC/NSCLC) — Biomica originated the consortium biology now licensed to Lishan.

Broad incumbents

• Ferring Pharmaceuticals: Large incumbent pharma with a microbiome franchise (partnered with Seres on VOWST and historical Rebyota approval) and a strong IBD/gastroenterology footprint. Comparable as the type of strategic partner or acquirer a clinical-stage LBP biotech like Lishan could partner with for global commercialization.

Emerging players

• Insilico Medicine: AI-native drug discovery company combining generative biology, multi-omics, and proprietary discovery platforms. Peer to Lishan on the AI/ML discovery side (overlaps with IMicAP's knowledge-graph + generative AI capabilities), although operating more in small-molecule discovery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lishan Biotech